mTOR抑制剂耐药机制及预测依维莫司疗效标志物的研究进展

Progress on Mechanism of Resistance to mTOR Inhibitor and Predicting Biomarkers for Everolimus Efficacy

依维莫司是一种哺乳动物雷帕霉素靶蛋白(mammalian target of rapamycin,mTOR)抑制剂,可改善晚期激素受体阳性/人表皮生长因子受体2阴性(hormone receptor-positive/human epidermal growth factor receptor 2-negative,HR+/HER2-)乳腺癌患者的预后。然而,依维莫司耐药日益发展,缺乏有效的标志物预测其疗效,对其临床应用造成了挑战。针对这一重要的临床问题,全文整理了近年来mTOR抑制剂的耐药机制及依维莫司疗效预测标志物的相关研究,以期提供参考。

Everolimus,a mammalian target of rapamycin(mTOR)inhibitor,has been shown to improve survival of patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative(HR+/HER2-)advanced breast cancer.However,resistance to everolimus has been increasingly developed,and there is no efficient biomarker to predict its efficacy,which becomes a challenge for the clinical use of everolimus.This paper reviews the mechanisms of resistance to mTOR inhibitor and potential markers that can predict the efficacy of everolimus.